Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor-Reference-Cited by-同舟云学术

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor

Published:2023-10-05 Issue:1 Volume:12 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Zhao Jingjing¹,Dong Jiebin¹,Deng Changwen²,Zhang Qianjing¹,Sun Shicheng¹,Li Honggang¹,Bai Yun¹,Deng Hongkui¹³

Affiliation:

1. Department of Cell Biology and MOE Engineering Research Center of Regenerative Medicine, School of Basic Medical Sciences, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Peking University, Hadian District, Beijing, China

2. Department of Respiratory and Critical Care Medicine, Shanghai East Hospital, School of medicine, Tongji University, Shanghai, China

3. College of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2023.2265703

Reference31 articles.

1. Chimeric Antigen Receptor Therapy

2. CAR T cell immunotherapy for human cancer

3. The blockade of immune checkpoints in cancer immunotherapy

4. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

5. Inhibitory B7-family molecules in the tumour microenvironment

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy;Frontiers in Immunology;2024-08-02

2. Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors;Seminars in Immunopathology;2024-07-25